Novel Drug Delivery System for Treating Diabetic Wounds

Information

  • Research Project
  • 6404006
  • ApplicationId
    6404006
  • Core Project Number
    R43DK060278
  • Full Project Number
    1R43DK060278-01
  • Serial Number
    60278
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/29/2001 - 23 years ago
  • Project End Date
    3/31/2003 - 21 years ago
  • Program Officer Name
    MOSHELL, ALAN N.
  • Budget Start Date
    9/29/2001 - 23 years ago
  • Budget End Date
    3/31/2003 - 21 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/15/2001 - 23 years ago

Novel Drug Delivery System for Treating Diabetic Wounds

DESCRIPTION (provided by applicant): The goal of this project is to demonstrate the feasibility of using a novel technology as a dual purpose wound dressing and drug delivery vehicle for the treatment of wounds associated with early stage diabetic foot ulcers. Diabetes is the leading cause of nontraumatic lower-extremity amputations in the United States. Foot ulceration is one of the most common components in the causal pathway to limb loss, and therefore, treatment and; prevention of diabetic ulcers is the central focus of amputation prevention programs. Despite significant morbidity resulting from diabetic foot wounds, there are no commonly accepted guidelines for treating and preventing their recurrence. The Specific Aims of the proposal are to: 1) Optimize the formulation of the delivery vehicle as a combination wound dressing and drug delivery system; 2) Evaluate the effects of the technology on epidermal cell growth in vitro; and 3) Demonstrate wound healing using a genetically diabetic mouse full thickness wound model. PROPOSED COMMERCIAL APPLICATION: Significant commercial potential exists for this product. Fifteen percent of diabetes patients will experience a foot ulcer in their lifetime, of which 14-28 percent will require an amputation. Early detection and appropriate treatment of these ulcers may prevent up to 80 percent of amputations, while significantly reducing the risk of infection, morbidity, and mortality.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    107000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:107000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOMEDICAL DEVELOPMENT CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782163610
  • Organization District
    UNITED STATES